Corteva, Inc. Form 8-K Summary
Business Context and Reporting Period
Corteva, Inc. filed this Form 8-K under Item 5.07 to report the results of its Annual Meeting of Stockholders held on April 29, 2022. The filing is a corporate-governance disclosure and does not cover a financial reporting period.
- Common stock outstanding and entitled to vote as of March 7, 2022: 726,773,605 shares.
- Shares voted in person or by proxy: 625,894,584, representing 86.11% of shares entitled to vote.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating or financial metrics.
Meeting Results and Material Changes
- Director elections: All 13 nominees were elected to serve until the next annual meeting and until their successors are elected or appointed. Votes against ranged from 1,764,051 to 47,692,184, excluding broker non-votes.
- Executive compensation: Stockholders approved, on an advisory basis, the compensation of the named executive officers: 526,740,947 for, 34,316,001 against, and 1,918,124 abstentions; broker non-votes totaled 62,919,512.
- Independent auditor: Stockholders ratified PricewaterhouseCoopers LLP as Corteva’s independent registered public accounting firm for 2022: 591,857,256 for, 33,183,113 against, and 854,215 abstentions.
The filing does not disclose material changes to operations, financial condition, strategy, or capital structure versus a prior comparable period.
Guidance, Outlook, Risks, and Unusual Items
No management guidance, outlook, risk updates, contingencies, or unusual operating items are disclosed. The principal disclosed matters are the election of directors, advisory approval of executive compensation, and auditor ratification.
Key Facts to Verify
- Confirm the composition and independence of the 13-member board elected at the meeting.
- Review the 2022 Proxy Statement for detailed director qualifications, compensation matters, and voting standards.
- Assess the significance of broker non-votes and the comparatively higher opposition to certain director nominees, particularly Gregory R. Page and David C. Everitt.
- Verify PricewaterhouseCoopers LLP’s appointment and any subsequent auditor or accounting developments in later filings.